Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SINO BIOPHARM To Present Research Results of 2 Innovative Drugs at ERS in Sep
Recommend 15 Positive 24 Negative 5 |
||||
|
||||
|
SINO BIOPHARM (01177.HK) announced that the research results of two innovative drugs developed by the Group, “TQC3721 (PDE3/4 inhibitor)” and “TQC2731 (TSLP monoclonal antibody)”, will be presented at the 2024 annual meeting of European Respiratory Society (ERS 2024) to be held on 7-11 September. TQC3721 is an inhaled PDE3/4 inhibitor intended for the maintenance therapy of chronic obstructive pulmonary disease (COPD) and is the second fastest developing drug in the world amongst innovative drugs with the same target. Currently, TQC3721 has completed phase I and phase IIa clinical trials, and its research data will be published at ERS 2024 in the form of poster, one of which is the Late Breaking Abstract. TQC2731 is a TSLP monoclonal antibody, currently undergoing phase II clinical trial in patients with asthma and chronic sinusitis with nasal polyps, and its development progress is among the fastest in the world. The phase I study data will be published in the form of a poster at ERS 2024. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
